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Background: To reduce sampling error associated with cancer detection in prostate needle biopsies, we explored
the possibility of using fluorescence in situ hybridisation (FISH) to detect chromosomal abnormalities in the
histologically benign prostate tissue from patients with adenocarcinoma of prostate.
Methods: Tumour specimens from 33 radical prostatectomy (RP) cases, histologically benign tissue from 17 of the
33 RP cases, and 26 benign prostatic hyperplasia (BPH) control cases were evaluated with Locus Specific Identifier
(LSI) probes MYC (8q24), LPL (8p21.22), and PTEN (10q23), as well as with centromere enumerator probes CEP8,
CEP10, and CEP7. A distribution of FISH signals in the tumour and histologically benign adjacent tissue was
compared to that in BPH specimens using receiver operating characteristic curve analysis.
Results: The combination of MYC gain, CEP8 Abnormal, PTEN loss or chromosome 7 aneusomy was positive in the
tumour area of all of the 33 specimens from patients with adenocarcinomas, and in 88% of adjacent histologically
benign regions (15 out of 17) but in only 15% (4 out of 26) of the benign prostatic hyperplasia control specimens.
Conclusions: A panel of FISH markers may allow detection of genomic abnormalities that associate with
adenocarcinoma in the field adjacent to and surrounding the tumour, and thus could potentially indicate the
presence of cancer in the specimen even if the cancer focus itself was missed by biopsy and histology review.
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Prostate carcinoma is the most common type of cancer in
men in the United States, with an estimated 241,740 new
cases in 2012 and 28,170 deaths [1]. It is the second lead-
ing cause of cancer death in US men after lung cancer.
The absence of reliable diagnostic markers that enable
early and accurate detection of carcinomas when they are
confined to the prostate is a fundamental problem in the
management of prostate cancer. The leading early de-
tection and diagnostic approach employs a combination
of DRE (digital rectal examination) and measurement
of serum PSA (prostate-specific antigen) followed by a* Correspondence: ekaterina.pestova@abbott.com
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reproduction in any medium, provided the orprostate biopsy. However, this approach has major limita-
tions. Out of the approximately 1.2 million patients who
undergo prostate biopsy each year in the US, 70% to 80%
receive negative results [2]. These patients cannot be com-
pletely reassured, however, because a cancer might have
been missed by sampling error due to the focal nature of
Prostate cancer (CaP) [3,4]. Therefore, each year about
840,000 to 960,000 men undergo repeat biopsies because
of consistently elevated PSA levels [4]. An additional chal-
lenge in prostate cancer diagnosis is that prostate cancer
is a multi-focal disease, with 67% to 96% of radical prosta-
tectomy specimens containing more than one focus of
disease [5-7]. Studies have shown that the use of more bi-
opsy cores may improve accuracy of diagnosis, reducing
the sampling effect [8]. Currently, a 12-core scheme isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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an acceptable sampling of the prostate gland [9], however,
collection of a higher number of biopsy cores is also being
considered [2]. Due to the potential comorbidity associ-
ated with collection of the high number of biopsy cores,
utilisation of molecular assays to improve the diagnostic
accuracy would be beneficial. Combined with conven-
tional histopathological assessment, predictive biomarkers
that indicate the high likelihood of the presence of malig-
nancy on a biopsy specimen without clearly malignant
histology could provide clinicians with guidance for strati-
fying individuals into those who need repeat biopsy or in-
tensive follow-up and those who do not.
The concept of “field cancerisation” or “field effect”
was first proposed by Slaughter et al. in 1953 when ob-
serving histological features of oral cancers [10] to de-
scribe the presence of histologically abnormal tissue
surrounding primary cancerous lesions. It was consid-
ered to cause the occurrence of multifocal tumours and
cancer recurrence. Due to the tremendous progress in
molecular biology and biotechnology, the definition of
field effect has been extended to the molecular abnor-
malities in tissues that appear histologically benign, as
defined by Höckel and Dornhöfer [11]: “the monoclonal
or multiclonal displacement of normal epithelium by a
genetically altered but microscopically undistinguishable
homologue.” Since then, the presence of the field effect
has been reported in various tumour types, including
carcinoma of the head and neck, lung, colon and rec-
tum, breast, stomach, prostate, and urinary bladder
[12,13].
Prostate cancer is multifocal disease, and field effect
may play a fundamental role in the development of
multifocal lesions. A recent review by Trujillo KA et.al
[14] summarized that field cancerisation of prostate can
occur at the levels of genetic, epigenetic, and biochem-
ical aberrations in structurally intact cells in histologi-
cally normal tissues adjacent to cancerous lesions.
Prostate cancer biomarkers of field cancerisation have
been studied by several groups using different strategies,
including nuclear morphology, DNA methylation, Mito-
chondrial DNA changes, mRNA profiling, protein ex-
pression and genomic DNA changes [14]. Genomic,
epigenetic, and biochemical alterations observed outside
the histologically visible tumour margins could result
from pre-existing fields of precursor cells in which can-
cer develops; alternatively, the tumour could have an
effect on the surrounding tissue, or the observed abnor-
malities could reflect both of the above effects [15]. The
question whether the field of molecular alterations is ex-
clusively of precursor nature, or whether it is induced by
the tumour, is still being discussed in the literature [14].
However, irrespective of their origin, the markers of field
cancerisation are associated with the cancer, and couldindicate the presence of cancer in the specimen if de-
tected in the tumour-adjacent histologically benign
tissue.
Although Florescence In Situ Hybridization technique
(FISH) represents a molecular technique that allows the
detection of numerical and structural genomic abnormal-
ities in interphase cell nuclei in tissue sections or cyto-
logical specimens such as deletion, amplification, and
translocation of various genomic regions in many types
of cancer [16,17], it has not been widely used in the stud-
ies on field cancerisation. Multiple chromosomal alter-
ations have been reported in CaP [18-20], including
chromosome aneusomy, gain of the 8q24 (MYC) locus,
and loss of 8p21-22 (LPL) [21], and 10q23 (PTEN),
among others [22]. In our initial feasibility study, we eval-
uated aberrations in multiple genomic loci involved in
tumorigenesis by FISH on a set of FFPE prostate adeno-
carcinoma specimens, and selected a group of probes
that detected cytogenetic abnormalities in these tumours.
The selected probes included LPL, MYC, PTEN, CEP7,
CEP 8, and CEP 10. In this study, using FISH technique,
we assessed whether these biomarkers could detect
chromosomal abnormalities that are present in the histo-
logically benign region adjacent to frank carcinoma.
Methods
FISH probes
A total of 6 probes including 3 centromeric probes
(CEP®) and 3 locus-specific identifiers (LSI®) were used.
CEP probes included CEP7 (SpectrumAqua™), CEP8
(SpectrumAqua), and CEP10 (SpectrumGreen™). LSI
probes were PTEN (SpectrumOrange™), MYC 8q24
(SpectrumGreen), and LPL 8p21-22 (SpectrumOrange).
All probes were obtained from Abbott Molecular, Inc.
(Des Plaines, IL).
Histological specimen collection
Thirty-three archived RP cases from patients with pros-
tate adenocarcinoma and 26 control Benign Prostatic
Hyperplasia (BPH) cases were provided by Rush Univer-
sity Medical Center (Approved IRB L06052503 waived
the requirement for informed consent). Multiple tissue
blocks were prepared from each of the RP cases. For
each specimen, 5 μm tissue sections were cut and placed
on positively charged microscope slides. The blocks were
characterised by staining one out of 10 serial sections
through the block with haematoxylin and eosin (H&E)
followed by examination by an expert pathologist. For all
33 cases, at least one block containing adenocarcinoma
was identified for this study and designated as “tumour”.
Region(s) with histopathological features of adenocarcin-
oma were marked by the pathologist on the H&E slides
of the tumour specimens. Twenty-five of the 33 adeno-
carcinoma cases were determined to have a Gleason
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had a Gleason score of 2–4. For 17 out of 33 adenocar-
cinoma cases used in this study, a second block was
identified that contained no recognisable histological
features of adenocarcinoma or prostatic intraepithelial
neoplasia (PIN) and designated as “histologically be-
nign.” It was estimated that histologically benign tissue
was spatially separated from the tumour margin on aver-
age by approximately 1 cm. The H&E images of the 17
histologically benign slides used in the study are pro-
vided in the Additional file 1. For the BPH cases, FFPE
blocks of TURP specimens were utilized. For each TURP
specimen, 5 μm tissue sections were cut and placed on
positively charged microscope slides. The blocks were
characterised by staining one out of 10 serial sections
through the block with haematoxylin and eosin (H&E)
followed by examination by an expert pathologist to
confirm that no histological features of adenocarcinoma
or prostatic intraepithelial neoplasia (PIN) are present.
The specimen slides used for the FISH assay proced-
ure were within 10 serial sections of the respective
H&E-stained slide to assure minimal separation of the
areas examined by FISH from the areas evaluated by
histopathology.
Histological sample pre-treatment and hybridisation
Formalin fixed paraffin embedded (FFPE) histological
specimen slides were baked at 56°C for 2–24 hours, then
were treated three times in Hemo-De (Scientific Safety
Solvents) for 5 minutes each at room temperature
followed by two 1-minute rinses in 100% ethanol at room
temperature. Slides were incubated in pre-treatment so-
lution (1× SSC, pH7.0) at 80°C for 35 minutes, rinsed for
3 minutes in deionized water, incubated 20–22 minutes
in 0.15% pepsin in 0.1 N HCl solution at 37°C, and rinsed
again for 3 minutes in deionized water. Slides then were
dehydrated for 1 minute each in 70%, 85%, and 100%
ethanol and air-dried. Two sets of probe hybridisation
mix were made: Probe mix 1 included CEP8 (Spectru-
mAqua), MYC 8q24 (SpectrumGreen), and LPL 8p21-22
(SpectrumOrange); Probe mix 2 consisted of CEP7
(SpectrumAqua), CEP10 (SpectrumGreen), and PTEN
(SpectrumOrange). Ten microliters of either probe hy-
bridisation mix containing blocking DNAs and LSI/WCP
Hybridisation Buffer (Abbott Molecular, Inc., Des Plaines,
IL) were added to a specimen, and a coverslip was ap-
plied with rubber cement sealed around. Slides and
probes were codenatured for 5 minutes at 73°C and hy-
bridized for 16–24 hours at 37°C on a ThermoBrite® hy-
bridisation platform (Abbott Molecular, Inc.). Following
hybridisation, coverslips were removed by soaking the
slides in 2× SSC/0.3% NP-40 for 2–5 minutes, and im-
mediately slides were washed in 2× SSC/0.3% NP-40 at
73°C for 2 minutes and subsequently in 1× SSC solution,PH ~ 7.0 for 1 minute at room temperature. The slides
were then allowed to dry in the dark. Ten microliters of
4',6-diamidino-2-phenylindole counterstain/antifade so-
lution (DAPI I, Abbott Molecular, Des Plaines, IL) was
added to the specimen, and a coverslip was placed on the
slide for microscopy.
FISH signal evaluation
The specimens were analysed under a fluorescence
microscope using single bandpass filters (Abbott Molecu-
lar, Des Plaines, IL) specific for DAPI, SpectrumOrange,
SpectrumGreen, and SpectrumAqua. The number of
FISH signals for each probe was recorded in a minimum
of 50 consecutive non-overlapped, intact interphase nu-
clei in areas of interest, which were identified by DAPI
staining of nuclei with reference to the corresponding
H&E-stained tissue. Tumour areas (tumour regions of
interest, ROI) scribed by the pathologist were evaluated
on the 33 RP specimen slides. For the 17 slides with his-
tologically benign tissue adjacent to tumour, representa-
tive areas were evaluated (histologically benign regions of
interest, ROI). Similarly, representative areas were evalu-
ated on BPH specimen slides.
Statistical analysis
For each specimen, 50–100 cells were enumerated with
respect to the number of fluorescent signals of each
probe. The following FISH abnormality parameters were
calculated for each probe:
 %Gain, percent cells with > 2 signals
 %Loss, percent cells with < 2 signals
 %Abnormal, percent cells with > 2 or < 2 signals
 For the two probe ratios (probe A/probe B),
%Gain is the percentage of cells with A/B ratio >1,
and %Loss is the percentage of cells with A/B
ratio < 1.
In order to screen for FISH probes potentially import-
ant for disease detection, the FISH parameters described
above were compared between different specimen
groups (tumour ROI vs. BPH, and histologically benign
ROI vs. BPH) using a two-sample t-test. FISH parame-
ters with significant p-values (p-value < 0.05) from the
t-test were selected for further examination.
After prioritizing potential FISH probes, the receiver
operating characteristic (ROC) method [23] was used to
select optimal FISH probe combinations, as well as the
optimal cut-off value for individual FISH probes. The
ROC curve is a plot of sensitivity versus 1-specificity or
false positive rate (FPR). In our study, each point on the
ROC curve represents a sensitivity/specificity pair corre-
sponding to a particular cut-off (for single FISH param-
eter) or a combination of cut-offs (for FISH parameter
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ideal (DFI) and the area under the curve (AUC) were
calculated.
DFI is defined as
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−sensitivityð Þ2 þ 1−specificityð Þ2
q
.
DFI represents the minimum distance from the ROC
curve to the value of a sensitivity of 1 and a false positive
rate (1-specificity) of 0. The DFI ranges from 0 to 1, with
0 being the ideal. Determination of the “optimal" cut-off
value is always a trade-off between sensitivity and speci-
ficity. Ideally, the “optimal" cut-off value provides both
the highest sensitivity and the highest specificity, easily
located on the ROC curve by finding the point with
minimum DFI. For determination of optimal cut-off
value, minimal DFI was used as the selection criterion.
The parameters with the determined cut-off below the
level of truncation for the FISH signals in FFPE tissue
specimens were not included in the further analysis. For
determination of optimal FISH probe combination, AUC
was used as the selection criterion. Statistically, the best
FISH probe combination is the one with largest AUC
values. For the selection of the final, optimized probe
set, scientific judgment was applied in combination with
the statistical analysis.
All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA.) on a UNIX operat-
ing system by Abbott Molecular Biostatistics and Data
Management Group.
Results
Detection of cytogenetic abnormalities by FISH in RP
specimens
In an initial feasibility study, we tested 16 RP specimens
from patients with adenocarcinoma of the prostate. Nine
out of the 16 specimens had a second section available
with only histologically benign tissue. Slides from 11 BPH
cases were used as controls. The probes included LSI
MYC (8q24), LPL (8p21.22), PTEN (10q23), and p16
(9p21), centromere probes CEP8, CEP10, CEP7, CEP3,
and CEP17, and TMPRSS2 break-apart. In the study, we
observed that tumour ROIs in radical prostatectomy spec-
imens bore chromosomal abnormalities, including MYC
amplification/gain, LPL and PTEN loss, TMPRSS2 re-
arrangement, as well as general aneuploidy. Importantly,
we also observed chromosomal abnormalities in some of
the 9 histologically benign slides from tumour patients.
The results demonstrated the feasibility of using a FISH
assay to detect chromosome abnormalities that are spe-
cific to specimens from adenocarcinoma patients. Based
on these initial results, we selected six probes that de-
tected chromosomal copy number abnormalities in most
RP specimens, both within tumour regions and extending
beyond histologically evident tumour. The six probes in-
cludedMYC, LPL, CEP8, PTEN, CEP10, and CEP7.We expanded the initial specimen set to the total of
33 RP specimens from patients with adenocarcinoma of
prostate and 26 BPH control specimens for the interro-
gation with the six selected FISH probes. For 17 out of
33 adenocarcinoma cases, in addition to the tumour re-
gion, we also evaluated tumour-adjacent histologically
benign tissue from the same specimen, using a separate
FFPE block that contained no histological features of
adenocarcinoma or prostatic intraepithelial neoplasia
(PIN) upon histopathological examination.
Chromosomal abnormalities of MYC, LPL and PTEN,
and aneusomy (as measured by copy number changes of
the chromosome-specific CEP probes) were observed in
tumour ROIs of the radical prostatectomy specimens.
Figure 1 shows images representing the copy number
gain of MYC (Figure 1A and B) and the loss of PTEN
(Figure 1C and D). Images were recorded within the
tumour ROI, which could also be recognized by the char-
acteristic pattern of nuclei under DAPI staining (Figure
1A and C). MYC signal was clearly gained (Figure 1B,
displaying 3 or 4 signals per cell in this specimen), while
PTEN signal was lost (Figure 1D), showing either zero or
one copies in the majority of cells within the ROI.
In this study, FISH analysis was performed on histo-
logical specimens. In contrast to cytology, FISH on FFPE
tissue specimens presents artefacts related to the nuclear
truncation. In our study, FISH analysis of individual sig-
nal counts showed a loss up to 10% of signals, with aver-
age counts of FISH probe signals per cell of 1.80-1.84 in
both test (RP) and control (BPH) tissue specimens.
Therefore, although truncation effects were evident, the
level of truncation did not appear to differ between test
and control cases. To further control for artefacts of nu-
clear truncation, the cut-offs for FISH positivity, espe-
cially for deletion probes, were chosen above the level of
truncation, as presented in the section Data Analysis of
Probe Performance below.
Sixteen parameters derived from genomic copy numbers
detected by FISH were evaluated by the t-test comparing
tumour ROI and BPH. These parameters were CEP10%
Abnormal, CEP10%Gain, CEP7%Abnormal, CEP7%Gain,
CEP8%Abnormal, CEP8%Gain, CEP8%Loss, MYC%Gain,
LPL%Abnormal, LPL%Loss, PTEN%Loss, PTEN/CEP10%
Loss, CEP7/CEP10%Gain, LPL/CEP8%Loss, MYC/CEP8%
Gain and MYC/LPL%Gain. Results from t-test analyses
demonstrated that for all of the 16 FISH parameters, mean
values were statistically different between tumour and BPH
groups (Additional file 2: Table S2a). Interestingly, chromo-
somal abnormalities were observed not only in the tumour
ROIs, but also on slides with the histologically benign tis-
sue approximately 1 cm away from the tumour margin of
the RP adenocarcinoma specimens (benign ROI).
Representative images demonstrating FISH and H&E
staining from a tumour section (Figure 2A, 2B, and 2C)
Figure 1 Images of abnormal FISH signals. A and B: The images of MYC SpectrumGreen copy number gain with DAPI staining (A) showing
the nuclei morphology, and MYC staining (B) displaying gain of copy numbers. C and D: the images of PTEN loss with DAPI staining (C) of the
tumour ROI, and PTEN FISH hybridisation showing deletion of PTEN in the prostate gland (D).
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2F) of the same case are shown in Figure 2. Figure 2A
presents an H&E image of a tumour section (from Case
01, tumour block) with the area of the tumour circled.
Figure 2D shows an H&E image of the histologically be-
nign section (from Case 01, histologically benign block)
with the area that had abnormal FISH signals circled.
Figure 2B and 2C show abnormal FISH in a representa-
tive field of view of the tumour section. Figure 2E and
2F show abnormal FISH from a representative field of
view of the histologically benign section. Figure 2B and
2E show MYC amplification (green signals indicated by
the red arrow) and DAPI nuclear staining (blue), while
Figure 2C and 2F show PTEN deletion indicated by
green arrows (gold PTEN signals are visible only in
stroma cells, indicated by white arrows) and DAPI nu-
clear staining (blue).
To confirm that the histologically benign areas se-
lected for the study were indeed devoid of tumour fea-
tures, we utilized a second, independent pathologist to
review the corresponding H&E images. Upon the in-
depth review of the suspected area, all but one specimen
were deemed to be histologically normal, since no fea-
tures of prostate adenocarcinoma, or PIN were observed
in these regions. In one apparently benign specimen
(sample number 33 block B), a very close, detailed in-
spection by the independent pathologist revealed pos-
sible minute tumour foci, however, the pathologist was
not able to conclusively classify the observed cells as
tumour without a suggested confirmation by other
methods (such as IHC), highlighting the challenges inhistopathological assessment of prostate tissue speci-
mens. Therefore, we confirmed that FISH detected cyto-
genetic abnormalities in the regions of prostate that
would not have been identified as tumour on histopath-
ology review.
Results from t-tests comparing histologically benign
ROI and BPH controls, showed that for 10 out of the
16 FISH parameters (Additional file 2: Table S2b), mean
values were statistically different between the comparison
groups. These 10 FISH parameters, derived from copy
numbers of MYC, LPL, CEP8, PTEN, CEP10 and CEP7,
were CEP10%Abnormal, CEP10%Gain, CEP7%Abnormal,
CEP7%Gain, CEP8%Abnormal, CEP8%Gain, MYC%Gain,
LPL% Abnormal, PTEN%Loss, PTEN/CEP10%Loss.
Analysis of probe performance and selection of optimal
probe combinations
The receiver operating characteristic (ROC) analysis
method was applied to the selected ten single FISH pa-
rameters. AUC values from the ROC analysis comparing
histologically benign ROIs from adenocarcinoma RP
specimens with BPH controls were used to assess the se-
lected FISH parameters in respect to their ability to dis-
tinguished adenocarcinoma specimens from the BPH
controls based on the presence of the genomic abnor-
malities extending beyond the tumour margin. Table 1
summarizes the sensitivity and specificity of the selected
FISH parameters at the optimal cut-off for each param-
eter. In this analysis, the cut-off was determined based
on the shortest Distance From Ideal (DFI) as described





Figure 2 Representative images of FISH and H&E staining from tumour and histologically benign areas of the same case. A: an H&E
image of a tumour section (from Case 01, tumour block) with the area of tumour circled; B: MYC amplification (green signals indicated by the red
arrow) and DAPI nuclear staining (blue) in a representative field of view of the tumour section; C: PTEN deletion indicated by green arrows and
DAPI nuclear staining (blue) in a representative field of view of the tumour section (gold PTEN signals are visible only in stroma cells); D: an H&E
image of the histologically benign section (from Case 01, histologically benign block) with the area that has abnormal FISH signals circled; E: MYC
amplification (green signals indicated by the red arrow) and DAPI nuclear staining (blue) in a representative field of view of the histologically
benign section; F: PTEN deletion indicated by green arrows and DAPI nuclear staining (blue) in a representative field of view of the histologically
benign section (gold PTEN signals are visible only in stroma cells, indicated by white arrows).
Table 1 ROC analysis (sensitivity, specificity, and the AUC) comparing ten selected FISH probe parameters
FISH probe
parameters
Tumour - BPH Histologically benign - BPH
Sensitivity Specificity AUC Sensitivity Specificity AUC
CEP8%Gain 79.40% 76.90% 0.853 82.40% 76.90% 0.871
MYC%Gain 91.20% 76.90% 0.908 82.40% 76.90% 0.846
CEP7%Abnormal 88.20% 80.80% 0.896 76.50% 80.80% 0.845
PTEN%Loss 58.80% 80.80% 0.726 70.60% 80.80% 0.827
PTEN/CEP10%Loss 82.40% 80.80% 0.881 64.70% 80.80% 0.788
CEP10%Gain 94.10% 84.60% 0.93 76.50% 84.60% 0.786
CEP10%Abnormal 79.40% 80.80% 0.865 76.50% 73.10% 0.775
CEP7%Gain 85.30% 84.60% 0.886 70.60% 76.90% 0.77
CEP8%Abnormal 94.10% 88.50% 0.966 64.70% 76.90% 0.752
LPL%Abnormal 79.40% 92.30% 0.945 64.70% 76.90% 0.736
The analyses of tumour ROI vs. BPH, and benign ROI vs. BPH performed independently. Sensitivity and specificity calculated at the optimal cut-off in each of the
two analyses for each parameter.
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specimens, as compared to BPH control.
The selected single FISH probe parameters listed in
Table 1 were then grouped in all possible 4-probe com-
binations, and the ROC method was used now to iden-
tify the optimal probe combinations based on their AUC
values and clinical consideration in distinguishing histo-
logically benign ROI specimens vs. BPH. Table 2 shows
the selected 4 probe combinations identified in this
analysis.
As evident from Table 2, probe combination 3 had the
highest AUC value of 0.938, while probe combination 1
had the second highest AUC value (0.917) and afforded
the lowest DFI (combined highest sensitivity and specifi-
city) at the indicated cut-offs. Since the achievable com-
bined sensitivity and specificity were noticeably higher
for probe combination 1, and since this probe combin-
ation also contained probes to two important tumour-
related loci, probe combination 1 was selected over
probe combination 3 despite the somewhat higher AUC
achieved with probe combination 3. The optimal cut-off
values chosen for the four individual FISH probe param-
eters in probe combination 1 are PTEN%loss > 33,
CEP7%Abnormal > 28, MYC%gain > 35, and CEP8%Ab-
normal > 34. Using these cut-offs, probe combination 1
yielded a sensitivity of 88.2% and a specificity of 84.6%
for histologically benign ROI vs. BPH (AUC = 0.917),
while the sensitivity and specificity for tumour ROI
vs. BPH were 100% and 84.6%, respectively, with the
AUC = 0.960.
ROC curves for the selected 4- probe combination,
and the corresponding 4 single FISH probe parameters,
including PTEN%loss, CEP7%Abnormal, MYC%gain,
CEP8%Abnormal, are plotted in Figure 3. The curves la-
belled ‘benign ROI’ were obtained from the FISH evalu-
ation comparing the 17 histologically Benign ROI to the
26 BPH specimens. The curve labelled ‘tumour ROI’ was
obtained from the evaluation comparing the 33 tumour
ROI to the 26 BPH. The corresponding AUC values forTable 2 ROC analysis of the selected four 4-probe combinatio
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Cut-off 1, cut-off 2, cut-off 3, and cut-off 4 are the optimal probe cut-offs (providingeach of the plotted ROC curves are listed in the table
under the ROC plot.
Discussion
Each year, millions of men are referred for prostate biop-
sies due to abnormal DRE or elevated serum PSA. Pros-
tate biopsies are not only unpleasant, but also carry risks
to the patient, and are expensive. Moreover, false-
negative rates for initial prostate biopsies (particularly
for sextant biopsies) are routinely reported to be be-
tween 10–25%, and repeat biopsies are essential compo-
nents of prostate cancer detection [24]. Therefore,
reliable diagnostic markers that enable early and accur-
ate detection of prostate tumours when they are con-
fined to the prostate are essential.
In this study, we tested LPL, MYC, PTEN, CEP 7, CEP
8, and CEP 10 FISH probes, based on the published
roles of these genes, and on our initial FISH study on
FFPE prostate cancer and BPH specimens. Sixteen pa-
rameters were derived from the number of FISH signals
at the above loci, and compared between prostate
adenocarcinoma tumour tissue (tumour ROI) and BPH
samples by the t-test. In this analysis, all 16 FISH param-
eters demonstrated a significant difference between the
comparison groups, supporting the role of these genes
in prostate cancer. In addition to the tumour ROIs, we
found FISH abnormalities in histologically benign tissue
separated from the tumour margin on average by ap-
proximately 1 cm (histologically benign ROI).
The pattern of FISH abnormalities in the histologically
benign ROIs was similar to that found in the corre-
sponding tumour (Additional file 3). The observed cyto-
genetic abnormalities appeared to be reflective of genetic
changes in the cancer cells of the associated tumour, in-
dicating the possibility that a field cancerisation effect
may be manifested in prostate cancer at the cytogenetic
level as a field of molecular alterations in adjacent, histo-
logically benign areas surrounding the tumour. Genomic
alterations observed outside the histologically visiblens from the 10 single FISH probe parameters
ff 2 Cut-off 3 Cut-off 4 Sensitivity Specificity AUC
P7%
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Figure 3 ROC curve. ROC plot for individual FISH probe parameters (PTEN%loss, CEP7%abnorm, MYC%gain, CEP8%abnormal) and the 4-probe
combination. Data were calculated from the FISH evaluation of the 17 benign ROI (histologically benign regions surrounding the tumour) and 26
BPH specimens. The ROC plot for the 4-probe combination of the 33 tumour ROI and 26 BPH specimens are also shown here. The AUC of the
ROC curves are shown in the table.
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precursor cells in which cancer develops; alternatively,
the tumour could have an effect on the surrounding tis-
sue, or the observed abnormalities could reflect both of
the above abnormalities [15]. We also cannot rule out
that the cells in which genomic abnormalities were de-
tected represent events related to the metastatic tumour
spread, such as undetected micro-metastases. However,
although FISH does not have an ability to establish
whether a cell under interrogation is a tumour cell, a
precursor cancer cell or a benign cell, cytogenetic abnor-
malities detected by FISH in our study were similar to
those in the associated tumour.
Not all chromosomal loci were detectable in the field
surrounding the tumour at the same level. Out of the ini-
tial sixteen FISH parameters chosen for evaluation, 10 were
identified that detected FISH abnormalities in histologically
benign ROIs of RP adenocarcinoma specimens, specific-
ally CEP10%Abnormal, CEP10%Gain, CEP7%Abnormal,
CEP7%Gain, CEP8%Abnormal, CEP8%Gain, MYC%Gain,
LPL%Abnormal, PTEN%Loss, PTEN/CEP10%Loss.By combining the individual FISH parameters, we
identified a probe combination (PTEN, MYC, CEP7 and
CEP8) that was superior in performance to that of indi-
vidual probes (Table 2 and Figure 3). In the specimen
set used in this study, with the optimal cut-offs for each
FISH parameter selected using the ROC method, the
sensitivity of the 4-probe combination was 88.2% and
the specificity was 84.6% for discriminating prostate
adenocarcinoma from BPH specimens based on cytogen-
etic abnormalities found in histologically benign regions
surrounding the tumour. Using the same cut-offs for
each FISH parameter, a sensitivity of 100% and a specifi-
city of 84.6% were achieved for discriminating prostate
adenocarcinoma from BPH specimens based on cytogen-
etic abnormalities found within the tumour. These find-
ings support the field cancerisation effect of prostate
cancer reported in several studies, including some of
the recent work of methylation changes [25], Telo-
mere attrition [26], Mitochondrial DNA changes [27],
and Gene expression changes [28,29]. Significantly,
evidence for such malignancy-associated changes has
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http://www.biomedcentral.com/1471-2407/14/129been presented in other organs such as the cervix, blad-
der and breast [11].
The results of our feasibility study of radical prostatec-
tomy suggest that multi-colour FISH may find utility in
detecting cytogenetic abnormalities associated with
adenocarcinoma of prostate in the field around the
tumour, and therefore could potentially aid in assessing
negative biopsies of patients with suspected cancer. The
hypothesis that FISH could be used to aid the detection
of adenocarcinoma by assessing the tissue surrounding
the tumour will be validated in the next phase of the in-
vestigation using prostate needle biopsy specimens.Conclusions
In this study of radical prostatectomy specimens, cytogen-
etic abnormalities were observed by FISH within regions
of prostate adenocarcinoma, as well as within regions of
benign histology extending beyond histologically evident
tumour margin, indicating a field cancerisation effect in
prostate cancer. Detection of field cancerisation by FISH
may prove to have a utility in the evaluation of histology-
negative biopsies from patients suspected of having pros-
tate cancer, and therefore could aid histopathological
evaluation by providing an indication of possible presence
of malignancy. Although preliminary, the findings of a
FISH panel with sensitivity >85% in histologically benign
regions away from tumour and specificity ~85% in BPH,
provide encouragement to pursue the utility of these cyto-
genetic markers further. Validation in a larger cohort of
patients with both positive and negative biopsies is envi-
sioned to confirm our findings.Additional files
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Additional file 2: t-test analyses. Table S2a. t-test of tumour ROI
vs BPH. Table S2b. t-test of histologically benign ROI vs BPH.
Additional file 3: The pattern of FISH abnormalities presents in the
33 tumour ROIs and the 17 available corresponding histologically
benign ROIs.Abbreviations
AUC: Area under the curve; BPH: Benign prostatic hyperplasia; CaP: Prostate
cancer; CEP: Centromeric probes; DRE: Digital rectal examination;
FFPE: Formalin fixed paraffin embedded; FISH: Fluorescence in situ
hybridisation; LSI: Locus specific identifier; PSA: Prostate-specific antigen;
ROC: Receiving operating characteristic; RP: Radical prostatectomy;
ROI: Region of interest.
Competing interests
Authors YZ, KP, LM have filed a pending patent application relating to the
subject matter of this article, which patent application has been assigned to
Abbott Molecular Inc.Authors’ contributions
YZ analysed the histological samples, performed the statistical analysis, and
drafted the manuscript. TP analysed the histological samples. BB analysed
the histological samples. JD performed the statistical analysis and helped to
draft the statistical section. PL performed the statistical analysis and helped
to draft the statistical section. DE assisted in the appropriate specimen
selection and sectioned the slides. JC provided clinical opinion, selected and
provided appropriate specimens and helped conceive the study, and scribed
the tumour region on the H&E slides. LM conceived the study and the study
design, provided guidance on data analysis, KP coordinated the study and
its design, analysed the histological samples, assisted in selection of probes,
performed the statistical analysis, and helped draft the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We thank John Schulz and Mona Legator (Abbott Molecular R&D) for
designing and manufacturing FISH probes for this study. We gratefully
acknowledge Dr. Klara Abravaya, Sr. Director of Abbott Molecular R&D, for
sponsoring this study and for the review of this manuscript. We also thank
Dr. Tracey Colpitts, Director of Abbott Molecular Technology Assessment for
helping to prepare response to the reviewers of this manuscript. We thank
Frank Policht for helping to take images.
Author details
1Abbott Molecular, Inc, 1300 East Touhy Avenue, Des Plaines, IL 60018, USA.
2Department of Pathology, Rush University Medical Center, 1750 West
Harrison Street, Chicago, IL 60612, USA.
Received: 1 August 2013 Accepted: 12 February 2014
Published: 25 February 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2012,
62:10–29.
2. Shariat SF, Roehrborn CG: Using biopsy to detect prostate cancer. Rev Urol
2008, 10(4):262–280.
3. Nonn L, Ananthanarayanan V, Gann PH: Evidence for field cancerization of
the prostate. Prostate 2009, 69:1470–1479.
4. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F,
Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la
Taille A: Prostate cancer detection rate in patients with repeated
extended 21-sample needle biopsy. Eur Urol 2009, 55:600–609.
5. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA:
Micro-focal prostate cancer: a comparison of biopsy and radical prosta-
tectomy specimen features. Eur Urol 2005, 48:895–899.
6. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L: Heterogeneity of
gleason grade in multifocal adenocarcinoma of the prostate. Cancer
2004, 100:2362–2366.
7. Qian J, Wollan P, Bostwick DG: The extent and multicentricity of
High-grade prostatic intraepithelial neoplasia in clinically localized
prostate adenocarcinoma. Hum Pathol 1997, 28:143–148.
8. de la Taille A, Antiphon P, Salomon L, Cherfan M, Porcher R, Hoznek A, Saint
F, Vordos D, Cicco A, Yiou R, Zafrani ES, Chopin D, Abbou CC: Prospective
evaluation of a 21-sample needle biopsy procedure designed to improve
the prostate cancer detection rate. Urology 2003, 61(6):1181–1186.
9. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA,
George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange
PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ,
Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC: NCCN clinical
practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw
2010, 8:162–200.
10. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral
stratified squamous epithelium; clinical implications of multicentric
origin. Cancer 1953, 6:963–968.
11. Höckel M, Dornhöfer N: The hydra phenomenon of cancer: why tumors
recur locally after microscopically complete resection. Canc Res 2005,
65(8):2997–3002.
12. Chai H, Brown RE: Review: field effect in cancer–an update. Ann Clin
Lab Sci 2009, 39(4):331–337.
13. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N,
Gentleman RC, True LD, Nelson PS, Lin DW: Differential gene expression in
Zhang et al. BMC Cancer 2014, 14:129 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/129benign prostate epithelium of Men with and without prostate cancer:
evidence for a prostate cancer field effect. Clin Canc Res 2010,
16:5414–5423.
14. Trujillo KA, Jones AC, Griffith JK, Bisoffi M: Markers of field cancerization:
proposed clinical applications in prostate biopsies. Prostate Canc 2012,
2012:302894.
15. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M:
Differential gene expression in tumoradjacent histologically normal
prostatic tissue indicates field cancerisation. Int J Oncol 2009, 35:537–546.
16. Bishop R: Applications of fluorescence in situ hybridization (FISH) in
detecting genetic aberrations of medical significance. Biosci Horiz 2010,
3(1):85–95.
17. Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G,
Mihatsch MJ, Moch H: Prognostic value of genomic alterations in invasive
cervical squamous cell carcinoma of clinical stage IB detected by
comparative genomic hybridization. Canc Res 1999, 59(14):3475–3479.
18. Makarov DV, Loeb S, Getzenberg RH, Partin AW: Biomarkers for prostate
cancer. Annu Rev Med 2009, 60:139–151.
19. Nelson WG, De Marzo AM, Isaacs WB: Mechanisms of disease prostate
cancer. N Engl J Med 2003, 349:366–381.
20. Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA:
Identification of numerical chromosomal changes detected by
interphase fluorescence in situ hybridization in high-grade prostate
intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab
Med 2002, 126(2):165–169.
21. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs
SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB: Homozygous deletion
and frequent allelic loss of chromosome 8p22 loci in human prostate
cancer. Cancer Res 1993, 53:3869–3873.
22. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA,
Squire JA: FISH analysis of 107 prostate cancers shows that PTEN
genomic deletion is associated with poor clinical outcome. Br J Cancer
2007, 97(5):678–685. Epub 2007 Aug 14.
23. Metz CE: Receiver operating characteristic analysis: a tool for the
quantitative evaluation of observer performance and imaging systems.
J Am Coll Radiol 2006, 3:413–422.
24. Yanke BV, Gonen M, Scardino PT, Kattan MW: Validation of a nomogram
for predicting positive repeat biopsy for prostate cancer. J Urol 2005,
173:421–424.
25. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR,
Mazumder A: Quantitative, spatial resolution of the epigenetic field effect
in prostate cancer. Prostate 2008, 68(2):152–160.
26. Joshua AM, Shen E, Yoshimoto M, Marrano P, Zielenska M, Evans AJ, Van
der Kwast T, Squire JA: Topographical analysis of telomere length and
correlation with genomic instability in whole mount prostatectomies.
Prostate 2011, 71(7):778–790.
27. Reguly B, Jakupciak JP, Parr RL: 3.4 kb mitochondrial genome deletion
serves as a surrogate predictive biomarker for prostate cancer in
histopathologically benign biopsy cores. J Canadian Urolog Assoc 2010,
4(5):E118–E122.
28. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli
M, Montironi R: Immunohistochemical expression of prostate tumor
overexpressed 1 in cystoprostatectomies with incidental and
insignificant prostate cancer. Further evidence for field effect in
prostatic carcinogenesis. Hum Pathol 2011, 42(12):1931–1936.
doi:10.1016/j.humpath.2011.02.014. Epub 2011 Jun 14.
29. Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK,
Davis MS, Smith AY, Griffith JK, Fischer EG, Bisoffi M: Early growth response
1 and fatty acid synthase expression is altered in tumor adjacent
prostate tissue and indicates field cancerization. Prostate 2012,
72(11):1159–1170. doi:10.1002/pros.22465. Epub 2011 Nov 29.
doi:10.1186/1471-2407-14-129
Cite this article as: Zhang et al.: Identification of FISH biomarkers to
detect chromosome abnormalities associated with prostate
adenocarcinoma in tumour and field effect environment. BMC Cancer
2014 14:129.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
